Congress Program

Monday, 19 February

 08:00  Registration
 08:50  Congress Opening and Welcome from Congress Chair
 09:00  Session I: Keynote Presentation
Moderator: Raanan Berger, Israel, Congress Chair

Pitfalls and Opportunities in Personalized Cancer Medicine: What Have We Learned?
Diane SimeoneLaura and Isaac Perlmutter Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center at NYU Langone Health, USA

 09:30  Session II:  Clinical Trials beyond the Patient
Moderator: Talia Golan, Israel, Organizing Committee

Oncology Clinical Trial Operations eg RECIST and Lugano Criteria
Rachel Schor-Bardach, Radiologist, Oncological Imaging and Cross-Sectional Imaging Section, Chaim Sheba Medical Center, Israel

Personalizing the Tumor Micro Environment in Clinical Trials
Aaron Goldman
, Associate Director, Research and Development and Immuno Oncology, Mitra Biotech, USA

Data Management in Oncology Clinical Trials 
Maria A. CrazeHeadquarters Director of Global Data Operations, Merck & Company, Inc, USA


 10:45  Coffee Break, Poster Viewing and visit the Exhibition
 11:15  Session III: Clinical Trials in Hematology 
 Clemens-Martin Wendtner, Germany

CAR T Cell Therapies Developed/Co-Developed by Celgene
Michael ZaiacVice President, Head of Haematology/Oncology Medical Affairs EMEA, Celgene, Switzerland

Fighting Hematological Diseases with an Innovative Approach: CAR-T Therapy
Simona Maria Paratore
, Medical Head, Cell and Gene Therapy, Novartis Oncology Region Europe, Italy

The GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] Framework for Clinical Trials in Hematology in Italy
Marco Vignetti, Dept. of Cellular Biotechnologies and Hematology, Sapienza University and Director, Central Office, GIMEMA Research Foundation, Rome, Italy

The German CLL Study Group
Clemens-Martin WendtnerDirector, Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich, Germany

The Impact of Clinical Trials in the Management of ALL
Sabina ChiarettiDiv. of Hematology, Dept. of Cellular Biotechnologies and Hematology, Sapienza University, Italy

 13:00 Lunch Break, Poster Viewing and visit the Exhibition
 14:00  Session IV: Finance & Oversight in Oncology Clinical Trials 
Moderator: Aliza Ackerstein, Israel, Organizing Committee

Budgeting Clinical Trials in Oncology
Ivana Matic, Global Operations Lead – Agreements
, MSD, Belgium  

How Pharma Companies Retain Ownership & Oversight in Pharma/CRO Alliance Models
Daniela Abbiento, Associate Director, Site Relationship and Operational Lead, Merck Group, Italy

Panel Discussion

Sponsored Lecture supported by GlobalCare Clinical Trials
Oncology Studies Facilitated by Taking Study Visits to the Patients
Gail Adinamis, Founder & CEO, GlobalCare Clinical Trials, USA

 15:30  Coffee Break, Poster Viewing and visit the Exhibition
 15:50  Session V: Pre-Clinical Models 
Moderators: Jens Siveke, Germany, Organizing Committee

Pre-Clinical Models and How they Influence Clinical Trial Decisions- The Physician Perspective (Pitfalls and Problems) 
Jens Siveke, Director, Division of Solid Tumor Translational Oncology at the partner site Essen of the German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) and Head of the Clinical Pancreatic Cancer Program at the West German Cancer Center, University Hospital Essen, Germany

Patient Xenograft Models: Tool for Preclinical Phase II Studies?
Jens Hoffmann, CEO, EPO-Berlin-Buch GmbH, Germany

Lost in Translation: Preclinical Modeling in Pancreatic Cancer - Where Do We Go from Here?
Vincenzo Corbo, University of Verona, Italy and  Michele Milella, Regina Elena National Cancer Institute, Italy 

 17:00  End of Day One

Tuesday, 20 February 

 07:30 Registration 
 08:30 Session VI: Precision Promise
Victoria Manax, USA

Victoria Manax, Chief Medical Officer, Pancreatic Cancer Action Network, USA

Precision Promise – A New Paradigm in Clinical Trial Design in Pancreatic Cancer 
Diane SimeoneLaura and Isaac Perlmutter Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center at NYU Langone Health, USA
Engaging Industry Partners in Non-Profit-Led, Innovative Clinical Trials: The Precision Promise Experience
Wendy Selig, Founder & CEO, WSCollaborative, USA

Design Innovations in Precision Promise: Adaptive Platform Clinical Trial in Pancreatic Cancer  
Donald Berry, Professor, Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, USA 


 10:30  Coffee Break, Poster Viewing and visit the Exhibition
 11:00  Session VII: Collaborative Organizations and Clinical Trials
Moderator: Michele MilellaItaly, Organizing Committee

Collaborative Organizations and Clinical Trials - The German Perspective
Salah-Eddin Al-Batran,
Medical Director, Institute of Clinical Cancer Research (ICCR), Krankenhaus Nordwest, 

The Italian Alliance Against Cancer (ACC) Collaborative Effort and a Perspective on Novel Methodological Approaches to Precision Oncology
Gennaro Ciliberto, 
Scientific Director, IRCCS Regina Elena National Cancer Institute, Italy 

 12:30  Lunch Break, Poster Viewing and visit the Exhibition
 13:30  Session VIII: Criticism, Audits and Inspections and Patient Advocacy
Moderator: Talia GolanIsrael, Organizing Committee

Criticism of Clinical Trials
Raya Leibowitz-Amit
Physician-Investigator, Chaim Sheba Medical Center, Israel

Auditing Oncology Clinical Trials: The FDA Perspective
Marcia Sherry-Newby, Principal Auditor, Chiltern, USA

Patient Advocacy in Clinical Trial Design
Tamir Gilat,
Chairman, Israel Cancer Research Fund, Israel

 15:00  Coffee Break, Poster Viewing and visit the Exhibition
 15:30  Session IX: Oral Presentations from Selected Abstracts
Moderator: Raanan Berger, Congress Chair

Dissecting Response to Targeted Agents in Preclinical Model of Colorectal Cancer (CRC): Role of the Microenvironment
Chiara Bazzichetto, Fabiana Conciatori, Italia Falcone, Francesco Cognetti,
Ludovica Ciuffreda, Michele Milella, Italy

Efficacy and Effectiveness of Checkpoint Inhibitors in Randomized Clinical Trials (RCTs) and in Real World Evidence (RWE): The case of Ipilimumab (IPI)
Diana Giannarelli
, Michele Milella, Sabrina Vari, Stefano Molica, Emilio Bria, Italy

A Randomized Controlled Trial of Ready to Use Therapeutic Food (RUTF ) For Moderate/Severe Acute Malnourished  Indian Children with Cancer 
Sneha Tandon, Brijesh Arora, Maya Prasad, Shripad Banavali, Gaurav Narula, Meera Gadge, Alka Jadhav, UK

 16:00  End of Congress